Consano Bio
CompanyUnited States
Consano Bio develops one asset, in phase 1 (C-1101 in chronic painful lumbosacral radiculopathy). Mostly other; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- Raised
- US$15m
- 0
- Trials
- 1
- Signal
Pipeline
1Potential first-in-class disease-modifying therapeutic for chronic sciatica
Phase 1, Other, chronic painful lumbosacral radiculopathy
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Funding rounds and grants1
- Signals1